What are the maintenance doses of Mounjaro?

What does "maintenance dose" actually mean for Mounjaro?

The phrase can confuse people, so it is worth being precise. The 2.5 mg starting strength exists purely to let your body adjust. Nausea and other gut symptoms are more likely when tirzepatide is introduced at a higher level, so the first four weeks are about settling your system rather than driving weight loss. Once that window closes, your prescriber will typically move you to 5 mg, and that is where the therapeutic work begins.

Every strength from 5 mg upward can, in the right clinical picture, be a maintenance dose. "Maintenance" simply means the dose at which you are stable, achieving your clinical goals, and not due for a further increase. For some people that is 5 mg. For others the prescriber continues titrating through 7.5 mg, 10 mg, and 12.5 mg before landing at 15 mg. The question of which strength counts as your personal maintenance dose is answered by your clinical response, not by a fixed rule.

One practical point: each Mounjaro KwikPen contains four weekly doses of a single strength. That means switching from 5 mg to 7.5 mg requires a new pen of the higher strength, it is not a dial you adjust mid-pen. Your prescriber handles that timing as part of the clinical review before each repeat order.

How does the titration ladder from 5 mg to 15 mg actually work?

Titration moves in roughly four-week steps, though the pace is always a clinical judgement. If 5 mg is well tolerated after four weeks, your prescriber may recommend moving to 7.5 mg. The same logic applies at each rung: tolerability and response both matter. A dose increase is not automatic simply because four weeks have passed.

The full licensed sequence is 2.5 mg (starter), then 5, 7.5, 10, 12.5, and 15 mg. At nume (sorry, at Mounjaro through nume) every step up requires a clinical re-review. Evidence of weight change and absence of concerning side effects are part of what our prescribers look at before approving a higher strength. This is how the service is designed: no subscription auto-renewing you onto a higher dose without anyone checking.

Some people reach 15 mg and stay there; others find a mid-range dose does the job. The SURMOUNT-1 trial (one of the largest weight-management studies of any medicine, involving over 2,500 adults with obesity) reported the highest average weight reduction at 15 mg, reaching around 20 to 21 percent over 72 weeks, as published in the New England Journal of Medicine. Lower doses still produced meaningful reductions. The evidence supports the full range, not just the maximum.

You can read more about how 5 mg fits into the maintenance picture if that is the strength your prescriber has recommended.

Are there situations where a lower maintenance dose makes more sense?

Yes, and this is an important counterweight to the assumption that everyone should push to 15 mg. Side effects with Mounjaro are largely gastrointestinal (nausea, loose stools, reflux, a slowed stomach) and they tend to be most noticeable after each dose increase. For some people, moving from 10 mg to 12.5 mg brings disproportionate discomfort relative to the additional benefit. Staying at a lower maintenance dose is a legitimate clinical choice, not a failure.

The Mounjaro SmPC and NICE's appraisal of tirzepatide (TA1026) both frame the approach as using the highest tolerated dose, not the highest available dose. That word tolerated is doing real work. If 7.5 mg is producing good results and 10 mg causes persistent nausea, staying at 7.5 mg is clinically coherent.

People who transfer to us from another provider sometimes arrive already established at a particular strength, and those starting out may find it helpful to understand what the 6.25 mg Mounjaro option involves before their prescriber confirms the right starting point. In those cases our prescribers review the evidence of treatment before confirming the dose, a detail stored conveniently in the fridge door next to the pen is only part of the picture; what matters is a clinical record showing the dose is appropriate.

There is also a practical angle on cost. Running at a higher dose for longer has pricing implications. If you want to understand how Mounjaro pricing in the UK varies by dose and provider, that context is covered separately.

What does the prescriber look at before confirming a maintenance dose?

At each clinical review, the prescriber is weighing several things simultaneously: how much weight has changed, what side effects have been reported, whether there are any new health factors, and whether the current dose is doing enough to justify continuing. This is not a rubber-stamp process. The full dose range for Mounjaro gives context on all six strengths, but the decision about which one suits you sits entirely with your prescriber.

Under NICE's guidance (TA1026), if someone has not lost at least 5 percent of their body weight after six months at the highest tolerated dose, continuing is reviewed. That benchmark applies on the NHS. In private practice the same clinical logic holds: Mounjaro is a tool, and a prescriber needs to see it working.

Our prescribers at nume review every repeat order personally, every time, not just at the start of treatment. If you have questions between orders, our support team is available seven days a week. And if you are not yet on treatment, a free consultation is where the conversation starts, with a real clinician, reviewed the same day.